Innovation Pharmaceuticals Announces License Agreement with Alfasigma S.p.A. for the Development and Commercialization of Brilacidin in Ulcerative Proctitis/Ulcerative Proctosigmoiditis

Ads

You May Also Like

Oncology Venture: Kallelse till extra bolagsstämma

INDKALDELSE TIL EKSTRAORDINÆR GENERALFORSAMLINGNOTICE TO CONVENE EXTRAORDINARY GENERAL MEETINGKALLELSE TILL EXTRA BOLAGSSTÄMMA Der indkaldes ...